Abstract

Background: The prevalence of extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-E) and carbapenemase-producing Enterobacterales (CPE) is now disseminated worldwide. This study aims to describe the prevalence of ESBL and CPE fecal carriage in colorectal cancer patients. Methods: All patients admitted to the oncology service of Amizour hospital (Algeria) for colorectal cancer chemotherapy from March to May 2019 were screened for ESBL-E or CPE fecal carriage. After culturing on chromogenic media, the presumptive colonies were identified by mass spectroscopy. Antibiotic susceptibility testing was performed according to the European Committee on Antimicrobial Susceptibility Testing. The β-lactamases encoding genes and plasmid-mediated quinolone-resistant genes were screened by PCR and sequencing. Results: ESBL-E strains were recovered from rectal swabs in 6 patients (14.3%) and only 1 patient (2.4%) was found a carrier for OXA-48-producing Klebsiella pneumoniae. The most frequently encountered species among ESBL-E was Escherichia coli (n = 5), followed by K. pneumoniae (n = 1). PCR and sequencing showed that four isolates harbored the blaCTX-M-15 gene and two strains harbored the blaCTX-M-14 gene. Also, one strain of K. pneumoniae was found to harbor both qepA and qnrS genes. Conclusion: This study highlighted the fecal carriage of ESBL-E and OXA-48-producing Enterobacterales strains in colorectal cancer patients.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.